Fig. 3: miR-99s and AKT1/mTOR expressions in breast cancer samples. | Cell Death & Disease

Fig. 3: miR-99s and AKT1/mTOR expressions in breast cancer samples.

From: Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA

Fig. 3: miR-99s and AKT1/mTOR expressions in breast cancer samples.

a–e RNA-seq data for expression of miR-99s (a–c), AKT1 (d), and mTOR (e) in the indicated subtype in The Cancer Genome Atlas (TCGA) database. Expression of AKT1 is negatively associated with the expression of miR-99a (f) and miR-100 (g) in breast cancer tissues in the TCGA PAN-CANCER breast database. The correlation between mTOR and miR-99a (h) or miR-100 (i). j–l Overall survival in patients with breast cancer stratified according to miR-99s expression status in their primary tumors. Survival time data are presented as means ± SEM. The log-rank test P value reflects the significance of the correlation between miR-99s positivity and longer survival outcome.

Back to article page